Liquidia LQDA NASDAQ · Healthcare · United States
$56.63 +0.41% +$0.23
Summary
37 / 100 · Bulios Score
What speaks for it
- Revenue grew by 115% a year over the last 3 years.
- It holds more cash than debt: $396.1M against $168.8M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 32 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 192% a year over 5 years. Over the last 3 years it grew by 115% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $94.2M.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $72.55 is 28% above today's price. 70% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 94%
- Service 6.3%
By region
The company reports no revenue by region.
Product brings in 94% of revenue.
Segments in detail